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Summary
Background Limited data are available on how often basal cell carcinomas (BCCs) are
clinically diagnosed without histological confirmation and how they are treated.
Objectives Within the framework of the EPIDERM project, an audit was conducted
in four European countries to study the occurrence of clinically diagnosed BCCs
without histological confirmation and to investigate how these are treated.
Methods In the Netherlands, Scotland, Finland and Malta studies were performed
within different timeframes. Patients with one or more BCC(s) were selected and
the number of clinically diagnosed BCCs without histological confirmation and
their treatment was investigated by (manually) reviewing the (electronic) patient
records and checking the (hospital) pathology databases to find evidence of
histological confirmation.
Results In the Netherlands, 1089 patients with a first histologically confirmed BCC
developed 1974 BCCs of which 1833 (92Æ9%) were histologically confirmed and
141 (7Æ1%) were not. A 4-month retrospective study conducted in Scotland
selected 294 patients with 344 BCCs; 306 (89Æ0%) were histologically confirmed
and 38 (11Æ0%) were not. A 3-month prospective study performed at the same
centre in Scotland identified 44 patients who developed 58 BCCs; 44 (75Æ9%) of
these were histologically confirmed and 14 (24Æ1%) were not. In Finland, there
were 701 patients who developed 977 BCCs, of which 807 (82Æ6%) were histo-
logically and 170 (17Æ4%) nonhistologically confirmed. In Malta, there were 420
patients with 477 BCCs. Only three (0Æ7%) of them were clinically diagnosed
without histological confirmation. In the Netherlands and Finland, clinically diag-
nosed BCCs without histological confirmation were most often treated with cryo-
therapy, whereas in Scotland 5% imiquimod cream was the preferred treatment
modality.
Conclusions Although the frequency of clinically diagnosed BCCs without histo-
logical confirmation differed between the four European regions (range 0Æ7–
24Æ1%), this confirms that the burden of BCC in Europe is underestimated when
based on data from pathology and ⁄or cancer registries.
Basal cell carcinoma (BCC) is the most common cancer among
caucasians and its incidence is increasing worldwide.1–5 The
growing number of patients with a history of BCC and ⁄or
multiple BCC, together with the costs related to treatment and
follow-up, make this skin cancer an increasingly important
public health problem.6,7
Most incidence and prevalence rates reported in the litera-
ture for BCC are based on data from cancer registries. How-
ever, only a few population-based cancer registries register
BCC information and most of them only collect the first histo-
logically confirmed BCC per patient.3,8 The large numbers
involved, the high prevalence of multiple BCCs within one
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patient on day of diagnosis, the practical problems in coding
‘multiple BCCs’, the number of cancer registry clerks needed
and the difficulties in accessing private clinics all prevent many
cancer registries from collecting (additional) BCC information.
Therefore, the exact size of the BCC problem is largely
unknown as a significant proportion of patients with BCC
develops multiple BCC over time and physicians may treat
clinically diagnosed BCC without histological confirmation. In
the last decade, the latter has become more common with the
introduction of new noninvasive treatments such as photo-
dynamic therapy and 5% imiquimod cream, which often have
better cosmetic outcome than standard surgery.9 Besides a pre-
vious Dutch report, there are limited data on how often BCC
gets diagnosed and treated without histological verification
and whether there are differences across Europe.10 Lack of
histological confirmation impedes registry of BCC in cancer
registries and consequently BCC incidence and prevalence data
will be lower than experienced by dermatologists.
Within the framework of the EPIDERM project, an audit
was conducted in four European countries (the Netherlands,
Scotland, Finland and Malta) to investigate the occurrence of
clinically diagnosed BCC without histological confirmation.11
Materials and methods
The Netherlands
This study has been described before.10 In short, a retrospect-
ive study was performed. All 1290 patients from four partici-
pating hospitals with a first histologically diagnosed BCC in
2004 were extracted from Eindhoven Cancer Registry (ECR).2
These patients were linked to PALGA, the Dutch nationwide
network and registry of histo- and cytopathology.12 The 1290
extracted patients were followed for subsequent histologically
confirmed BCCs until 1 November 2010 or date of death,
whichever came first. BCC case definition has been described
before.7 Twenty-nine patients could not be retrieved from
PALGA, 23 already had a histologically confirmed BCC prior
to 2004, 149 had incomplete or missing patients records or
were never seen by a dermatologist; therefore 1089 patients
were considered eligible for this study. Among these patients,
the number of nonhistologically confirmed BCCs and the treat-
ment methods for histologically and nonhistologically con-
firmed BCCs were registered by manually reviewing the
patient records of these individuals between 14 January and
28 March 2011.
Scotland
A 4-month retrospective study and a 3-month prospective study
were carried out in the dermatology department of Ninewells
Hospital, Dundee, to estimate the proportion of BCCs seen that
were clinically diagnosed without histological confirmation and
therefore never recorded on a histopathology or cancer registry
database. Clinical details in the form of a general practitioner let-
ter are registered in an electronic clinical database (Dermabase,
NHS, Tayside, Scotland, UK) for all patients attending the
department of dermatology. A Dermabase record is generated
after every dermatology appointment and therefore an individ-
ual patient may have multiple Dermabase records. This Derm-
abase record includes a diagnosis recorded either as ‘active
diagnosis’ or ‘inactive diagnosis’. In case there were deficiencies
in tracking all BCCs using Dermabase, a prospective study was
conducted as well, whereby all patients attending a selection of
outpatient clinics were audited over a 3-month period.
Four-month retrospective study
Electronic patient records in Dermabase with an active diagno-
sis of ‘basal cell carcinoma’ were identified between 1 Septem-
ber and 31 December 2009, representing 310 patients. For
each patient, the hospital pathology database was searched
from 1 September 2009 until 31 May 2010, allowing five
additional months to accommodate delays in surgical treat-
ment. Nine patients were excluded because neither pathology
data nor Dermabase letters were available, or because the
Dermabase entries represented first appointments that were
not attended. Two patients were excluded because the diagno-
sis of BCC was in fact ‘inactive’ and five patients because they
were recorded under ‘basal cell carcinoma’ when they had a
diagnosis of basal cell papilloma. In total, 294 patients with
an active diagnosis of BCC were included in this study. For
those with and without evidence of histological confirmation,
Dermabase was interrogated to find the method of treatment.
No information was collected on the histopathological sub-
types and anatomical localization of the included BCCs.
Three-month prospective study
Seventy-seven patients attending dermatology clinics at Nine-
wells Hospital, Dundee between 11 January and 11 April
2010 and identified as presenting with a BCC were studied.
Forty-four of these 77 had one or more BCC(s) correctly diag-
nosed at that clinic appointment and were included in the
audit, whereas the remainder had the initial clinical diagnosis
of BCC made prior to the study period and were therefore
excluded. For each patient, the pathology database was
searched between 10 January and 31 May 2010 to look for
receipt of a BCC specimen after the appointment at which the
clinical diagnosis of BCC was made. For those with and with-
out evidence of histological confirmation, Dermabase was
interrogated to find the method of treatment. No information
was collected on the histopathological subtypes and anatomical
localization of the included BCCs.
Finland
Between 1 October and 31 December 2009 a retrospective
and between 1 January and 31 March 2010 a prospective
study was performed at the department of dermatology of the
Skin and Allergy Hospital, Helsinki University Central Hospital
in Helsinki (the regional centre for dermato-oncology). All
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skin cancer patients who visited the department of dermatol-
ogy during these 6 months were included. During this study
period, 701 patients were diagnosed or treated for one or
more BCC(s). In June 2010 the hospital pathology database
was checked to verify histologically confirmed BCCs, allowing
two additional months to accommodate delays in surgical
treatment. In the retrospective part of the study the patient
records were investigated to find the method of treatment; in
the prospective part the method of treatment was recorded
after the appointment. No information was collected on the
histopathological subtypes and anatomical localization of the
included BCCs.
Malta
Between 1 October 2009 and 31 March 2010, all hospitals
and clinics both public and private (Mater Dei Hospital, St
James Hospital, St Philip’s Hospital, Dr Deguara’s laboratory,
the oncology department and St Mark’s laboratory) were vis-
ited to collect and count all patients with a BCC between 1
January and 31 December 2009, by going through all hospital
pathology databases, patient records, oncology reports and
notifications. When a BCC was mentioned in the patient
record, oncology report or in a notification, but not found in
the pathology database, it was considered a clinically diag-
nosed BCC without histological confirmation. When a patient
presented with multiple BCC on the day of diagnosis, only the
localization of one BCC was registered in the Maltese Cancer
Registry. If available within the hospital pathology database,
the histopathological subtype of the BCC was registered.
Results
The Netherlands
After combining the data from PALGA, ECR and the hospital
patient records, 1974 BCCs were diagnosed among 1089
patients.10 Overall, the patients contributed 6253 person-years
of follow-up. The mean ± SD age at date of first histologically
confirmed BCC was 65Æ0 ± 14Æ0 years. The male ⁄ female ratio
was 1 : 1. Of the 1974 BCCs, 1833 (92Æ9%) were histologically
and 141 (7Æ1%) were nonhistologically confirmed (Table 1).
Surgical excision (83Æ6%) was the most performed treat-
ment modality, followed by cryotherapy (6Æ1%) and photody-
namic therapy (2Æ8%). This distribution was the same for
histologically confirmed BCCs (Table 2). For nonhistologically
confirmed BCCs, cryotherapy (65Æ2%) was the predominant
treatment, followed by photodynamic therapy (23Æ4%), 5-flu-
orouracil (4Æ3%) and imiquimod cream (4Æ3%).
Scotland
Four-month retrospective study
In total, 344 BCCs were recorded in 294 patients: 156
(53Æ1%) men and 138 (46Æ9%) women. The mean ± SD age Ta
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at date of diagnosis was 70Æ5 ± 12Æ4 years. Of the 344 BCCs,
306 (89Æ0%) were histologically confirmed and 38 (11Æ0%)
were not confirmed histologically (Table 1).
Most BCCs were treated surgically (87Æ2%), followed by
imiquimod cream (4Æ9%) and cryotherapy (2Æ3%). All but one
histologically confirmed BCC were treated with simple surgical
excision or Mohs micrographic surgery. One was treated with
radiotherapy. For nonhistologically confirmed BCC, imiqui-
mod cream (44Æ7%) was the preferred treatment method,
followed by cryotherapy (21Æ1%) and 5-fluorouracil cream
(Table 3).
Three-month prospective study
The 44 patients diagnosed with a BCC between 11 January
and 11 April 2010 had a total of 58 BCCs. The patients com-
prised 24 (54Æ5%) men and 20 (45Æ5%) women. The
mean ± SD age at diagnosis was 71Æ2 ± 10Æ7 years. Of the 58
BCCs, 44 (75Æ9%) were histologically and 14 (24Æ1%) were
not histologically confirmed (Table 1). The mean ± SD num-
ber of BCCs diagnosed at the date of appointment was
1Æ3 ± 0Æ82 (range 1–5).
Taking the retrospective and prospective audits together,
most BCCs were treated surgically (86Æ8%), followed by im-
iquimod cream (7Æ0%) (data not shown). All histologically
confirmed BCCs were treated with surgical excision. For BCCs
without histological confirmation, imiquimod cream (53Æ8%)
was the preferred treatment, followed by cryotherapy (15Æ4%)
and overall for 10 BCCs it was decided to observe and not to
treat because the patients were elderly and frail.
Finland
Among the 701 included patients there were 327 (46Æ6%)
men and 374 (53Æ4%) women. In total, they developed 977
BCCs during the study period. The mean ± SD age at diagno-
sis was 72Æ3 ± 12Æ8 years. Of the total 977 BCCs, 807 were
histologically confirmed (82Æ6%) and 170 (17Æ4%) were non-
histologically confirmed (Table 1).
Most BCCs were treated with standard surgical excision
(57Æ1%), followed by cryotherapy (28Æ4%) and photodynamic
therapy (11Æ8%). For three patients the therapy was missing
because they died before they were treated. For histologically
confirmed BCC, the distribution was similar. Nonhistologically
Table 2 Dutch study: treatment per basal cell carcinoma (BCC)
Treatment
Total number
BCCs (n = 1974), n (%)
Histologically confirmed BCCs
(n = 1833), n (%)
Nonhistologically confirmed
BCCs (n = 141), n (%)
Surgical excision 1650 (83Æ6) 1650 (90Æ0) –
Mohs micrographic surgery 20 (1Æ0) 20 (1Æ1) –
Cryotherapy 121 (6Æ1) 29 (1Æ6) 92 (65Æ2)
Photodynamic therapy 56 (2Æ8) 23 (1Æ3) 33 (23Æ4)
5-Fluorouracil cream 10 (0Æ5) 4 (0Æ2) 6 (4Æ3)
Imiquimod cream 8 (0Æ4) 2 (0Æ1) 6 (4Æ3)
Diclofenac gel – – –
Curettage 14 (0Æ7) 14 (0Æ8) –
Tretinoin – – –
Radiotherapy – – –
Expectative ⁄not treated 4 (0Æ2) 2 (0Æ1) 2 (1Æ4)
Missing 91 (4Æ6) 89 (4Æ9) 2 (1Æ4)
Table 3 Scottish 4-month retrospective study: treatment per basal cell carcinoma (BCC)
Treatment
Total number BCCs
(n = 344), n (%)
Histologically confirmed
BCCs (n = 306), n (%)
Nonhistologically confirmed
BCCs (n = 38), n (%)
Surgical excision 300 (87Æ2) 300 (98Æ1) –
Mohs micrographic surgery 5 (1Æ5) 5 (1Æ6) –
Cryotherapy 8 (2Æ3) – 8 (21Æ1)
Photodynamic therapy – – –
5-Fluorouracil cream 5 (1Æ5) – 5 (13Æ2)
Imiquimod cream 17 (4Æ9) – 17 (44Æ7)
Diclofenac gel 1 (0Æ3) – 1 (2Æ6)
Curettage – – –
Tretinoin – – –
Radiotherapy 1 (0Æ3) 1 (0Æ3) –
Expectative ⁄not treated 7 (2Æ0) – 7 (18Æ4)
Missing – – –
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confirmed BCCs were most often treated with cryotherapy
(77Æ1%) and the remainder with photodynamic therapy
(22Æ9%) (Table 4).
Malta
Of the 420 included patients, there were 256 (61Æ0%) men and
264 (39Æ0%) women. In total, they developed 447 BCCs. The
mean ± SD age at diagnosis was 65Æ9 ± 13Æ8 years. Only three
(0Æ7%) of the 447 tumours were diagnosed clinically without
histological confirmation (Table 1). The most common site was
the head and neck area (n = 256), followed by trunk (n = 67),
upper extremities and shoulders (n = 28) and lower extremities
(n = 22). This excluded 47 BCCs for which site was not regis-
tered. The histopathological subtype was unspecified in 412
(92Æ2%) BCCs. Of the remainder, 30 BCCs (6Æ7%) were superfi-
cial, while five (1Æ1%) had infiltrative growth pattern. No
detailed information was available on the treatments used.
Discussion
The frequency of clinically diagnosed BCC treated without
histological confirmation differed between the four European
regions (range 0Æ7–24Æ1%), the highest proportion being
observed in the small prospective study in Dundee, Scotland.
This contrasts with the findings of a previous study in 1997
from Glasgow (3Æ8%), which suggested that dermatologists
rarely treat clinically suspicious tumours without histological
proof of diagnosis.13 Either practice varies significantly across
Scotland or (more likely) dermatological practice has changed
with the advent and greater availability of nonsurgical treat-
ments such as imiquimod cream and photodynamic therapy.
A previous study among French dermatologists found that
14Æ1% of the clinically suspicious BCCs were not histologically
confirmed, which is not dissimilar from the percentages
observed in Finland (17Æ4%) and in the retrospective study
performed in Dundee, Scotland (11Æ0%).14
Malta, with < 1%, had the lowest percentage of BCCs diag-
nosed without histological confirmation. After interviewing
the Maltese dermatologists (n = 12) about their practices of
treating patients, they all confirmed that it was custom to
verify all clinically suspicious BCCs histologically with biopsy
and ⁄or surgical excision. In the Netherlands, the number of
subsequent clinically diagnosed BCCs without histological
confirmation (developed during a mean follow-up period of
almost 6 years) was investigated in patients with a prior
histologically confirmed BCC. This differs from the study
design of the other three European regions in which there
was no selection of patients who already had a first, histo-
logically confirmed BCC. Besides dissimilarities in practice
and study design, also differences in insurance reimburse-
ments between the European regions may account for the
wide variation found in the percentage of clinically diagnosed
BCC. However, the latter should not be such a large factor as
in all four European regions BCCs do not need histological
confirmation for patients to receive insurance reimbursements
(based on personal communications with Sari Pitka¨nen, Rita
Micallef and Esther de Vries).
This study confirms an underestimate of the absolute BCC
number based on histologically confirmed BCC alone and
illustrates that previous studies based on cancer registries
and ⁄or pathology databases will have underestimated the true
BCC burden. Therefore, health care policy makers (especially
in the Netherlands, Scotland and Finland) should incorporate
the proportion of BCCs treated without histological confirm-
ation into their calculations (in Malta this seems to be a less
of a problem). This is especially important as in all four Euro-
pean regions the ratio of dermatologists to the total popula-
tion is dramatically low, ranging from 1 to 3Æ6 per 100 000
inhabitants.15
In the Netherlands, Scotland and Finland, the preferred
treatment modality for histologically confirmed BCC is stan-
dard surgical excision, followed by cryotherapy (the Nether-
lands and Finland) and imiquimod cream (Scotland). No
detailed data were available for Malta; however, it seems that
most are surgically excised (based on personal communica-
tion). In the Netherlands and Finland, for clinically diagnosed
BCC without histology, cryotherapy was the treatment used
Table 4 Finnish study: treatment per basal cell carcinoma (BCC)
Treatment
Total number
BCCs (n = 977), n (%)
Histologically confirmed
BCCs (n = 807), n (%)
Nonhistologically confirmed
BCCs (n = 170), n (%)
Surgical excision 558 (57Æ1) 558 (69Æ1) –
Mohs micrographic surgery 23 (2Æ4) 23 (2Æ9) –
Cryotherapy 278 (28Æ4) 147 (18Æ2) 131 (77Æ1)
Photodynamic therapy 115 (11Æ8) 76 (9Æ4) 39 (22Æ9)
5-Fluorouracil cream – – –
Imiquimod cream – – –
Diclofenac gel – – –
Curettage – – –
Tretinoin – – –
Radiotherapy – – –
Expectative ⁄not treated – – –
Missing 3 (0Æ3) 3 (0Æ4) –
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most often, followed by photodynamic therapy. In Scotland,
imiquimod was the preferred treatment, then cryotherapy.
A limitation of this study was the methodological differ-
ences between the substudies performed in the four European
regions. The study design was notably different in the Nether-
lands, where patients with a first histologically confirmed BCC
in 2004 from four dermatology departments were followed
for subsequent clinically diagnosed BCCs. In Scotland and Fin-
land, the audits were performed at hospital level, while in
Malta all hospitals and clinics were investigated for clinically
diagnosed BCC. This was possible for Malta because of its
small size and contained geographical region. In addition, the
cancer registry in Malta recorded all BCCs for which there was
a histological diagnosis. Another important variation was the
size of the study populations. Although the prospective Scot-
tish study observed the highest percentage of BCC diagnosed
clinically without histology, this study also had the smallest
study population, which may have inflated the proportion.
None the less, the greater proportion of BCCs without histo-
logical diagnosis identified in this prospective study compared
with the retrospective study from the same department dem-
onstrates the importance of prospective investigation. This
potential problem of missed BCCs in retrospective studies was
largely avoided by interrogating hospital case notes for all
included patients in the other substudies.
A French medical cost analysis study described that when
histological confirmation was performed in clinically suspi-
cious superficial BCCs, a diagnosis of BCC was confirmed in
85% of cases.16 Additionally, a study from the U.S.A. sug-
gested that the positive predictive value of the clinical diagno-
sis of a BCC is only 80%, and that is when the dermatologist
is reasonably confident about the diagnosis.17 Therefore, the
observed percentages of clinically diagnosed BCC without
histological confirmation within this study may be an overesti-
mate. These limitations and the differences identified between
the substudies from four different European regions suggest
that our data are an estimate for the number of clinically diag-
nosed BCC and may not be representative for Europe as a
whole.
In conclusion, limited data are available about the frequency
of clinically diagnosed BCCs without histological confirmation
and their treatment. Although the percentage of nonhistologic-
ally confirmed BCCs differed between the four European
regions, our findings confirm that the burden of BCCs is
underestimated when based solely on data from pathology
records and ⁄or cancer registries.
What’s already known about this topic?
• Cancer registry data only include histologically con-
firmed tumours.
• It is not known how often basal cell carcinomas (BCCs)
are diagnosed without histological confirmation nor
how these histologically unconfirmed BCC are treated.
What does this study add?
• The frequency of BCC diagnosed without histological
confirmation differed widely between four European
regions (the Netherlands, Scotland, Finland and Malta),
ranging from 0Æ7% to 24Æ1%.
• In the Netherlands and Finland, clinically diagnosed
BCCs without histological confirmation were most often
treated with cryotherapy, whereas in Scotland 5% imiq-
uimod cream was the preferred treatment modality.
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Other members of the EPIDERM group involved in this study
are as follows. Erasmus MC University Medical Center Rotter-
dam, the Netherlands: Jan Willem Coebergh; First and Second
Departments of Dermatology and Venereology, Aristotle Uni-
versity, Thessaloniki, Greece: Dimitrios Ioannides, Dimitrios
Kalabalikis, Dimitrios Sotiriadis, Myrto Trakatelli; Dermatology
Unit, Hospital Universitario Virgen Macarena, Seville, Spain:
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Department of Dermatology, Sir Paul Boffa Hospital, Floriana,
Malta: Sue Aquilina, Lawrence Scerri, Charmaine Apap;
Department of Dermatology and Allergology, Helsinki Univer-
sity Central Hospital, Helsinki, Finland: Annamari Ranki;
Department of Dermatology, Skin Cancer Center, Charite´-Uni-
versita¨tsmedizin Berlin, Germany: Eggert Stockfleth, Martina
Ulrich, Birgit Hinrichs, Efthymios Altsitsiadis; Department of
Dermatology, University of Modena and Reggio Emilia, Italy:
Cristina Magnoni, Chiara Fiorentini; Department of Dermatol-
ogy and Venereology, Medical University of Warsaw, Warsaw,
Poland: Slawomir Majewski; Skin Tumour Laboratory, Medical
Research Institute, Ninewells Hospital and Medical School,
Dundee, U.K.: Leaca Crawford, Colin Fleming, James Gibbs;
Research Group Marketing, Faculty of Business and
Economics, Katholieke Universiteit Leuven, Belgium: Efthy-
mios Altsitsiadis.
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